Literature DB >> 2591128

Rheumatoid arthritis and chronic lymphatic leukaemia.

H G Taylor1, N Nixon, T P Sheeran, P T Dawes.   

Abstract

There is evidence for an increased incidence of lymphoproliferative disorders in patients with rheumatoid arthritis (RA). We present the clinical features of 4 patients with RA and chronic lymphatic leukaemia (CLL) which, occurring in a population of 1505 RA patients, represents a significantly increased prevalence of CLL (p less than 0.05) compared to the general population. These patients had significantly lower natural killer cell activity than matched rheumatoid controls (p less than 0.05) or normal controls (p less than 0.01) and we discuss this as a possible mechanism of association.

Entities:  

Mesh:

Year:  1989        PMID: 2591128

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  5 in total

Review 1.  Rheumatologic manifestations of benign and malignant haematological disorders.

Authors:  Vinod Ravindran; Parameswaran Anoop
Journal:  Clin Rheumatol       Date:  2011-06-23       Impact factor: 2.980

2.  Prior medical conditions and the risk of adult leukemia in Shanghai, People's Republic of China.

Authors:  W Zheng; M S Linet; X O Shu; R P Pan; Y T Gao; J F Fraumeni
Journal:  Cancer Causes Control       Date:  1993-07       Impact factor: 2.506

3.  Heredofamilial deficiency of monocyte esterase in patients with rheumatoid arthritis.

Authors:  A L Bell; G M Markey; M D McCaigue; D Middleton; J A McCormick; A G Wilson; T C Morris
Journal:  Ann Rheum Dis       Date:  1992-05       Impact factor: 19.103

Review 4.  Chronic lymphocytic leukemia and autoimmunity: a systematic review.

Authors:  Kate Hodgson; Gerardo Ferrer; Emili Montserrat; Carol Moreno
Journal:  Haematologica       Date:  2011-01-17       Impact factor: 9.941

5.  Risk of cancer among rheumatoid arthritis patients in California.

Authors:  Arti Parikh-Patel; Richard H White; Mark Allen; Rosemary Cress
Journal:  Cancer Causes Control       Date:  2009-01-28       Impact factor: 2.506

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.